You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAzelastine
Accession NumberDB00972  (APRD00813)
TypeSmall Molecule
GroupsApproved
DescriptionAzelastine, a phthalazine derivative, is an antihistamine and mast cell stabilizer available as a nasal spray for hay fever and as eye drops for allergic conjunctivitis. Azelastine is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patient over 12 years old for symptomatic relief of seasonal allergic rhinitis.
Structure
Thumb
Synonyms
4-(P-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone
Azelastina
Azelastinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AstelinSpray, metered137 ug/1NasalMeda Pharmaceuticals Inc.1996-11-152016-11-30Us
AstelinSpray, metered137 ug/1NasalPhysicians Total Care, Inc.2004-05-25Not applicableUs
AsteproSpray, metered205.5 ug/1NasalMeda Pharmaceuticals Inc.2009-10-12Not applicableUs
Azelastine HydrochlorideSpray, metered205.5 ug/1NasalPerrigo New York Inc2015-04-092018-03-01Us
Azelastine HydrochlorideSpray, metered137 ug/1NasalWallace Pharmaceuticals Inc.2010-07-01Not applicableUs
Azelastine HydrochlorideSolution / drops.5 mg/mLIntraocularWallace Pharmaceuticals Inc.2010-10-01Not applicableUs
Azelastine HydrochlorideSpray, metered205.5 ug/1NasalWallace Pharmaceuticals Inc.2015-04-01Not applicableUs
OptivarSolution / drops.5 mg/mLIntraocularMeda Pharmaceuticals Inc.2000-05-22Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Azelastine HCl NasalSpray205.5 ug/1NasalPerrigo New York Inc2014-05-09Not applicableUs
Azelastine HydrochlorideSolution / drops.5 mg/mLIntraocularSandoz Inc2013-03-21Not applicableUs
Azelastine HydrochlorideSolution / drops.5 mg/mLOphthalmicAkorn, Inc.2016-11-08Not applicableUs
Azelastine HydrochlorideSpray, metered137 ug/1NasalPhysicians Total Care, Inc.2011-06-28Not applicableUs
Azelastine HydrochlorideSpray, metered137 ug/.137mLNasalAv Kare, Inc.2016-04-01Not applicableUs
Azelastine HydrochlorideSpray, metered137 ug/1NasalSun Pharma Global FZE2012-05-24Not applicableUs
Azelastine HydrochlorideSpray, metered137 ug/1NasalA S Medication Solutions2010-03-01Not applicableUs
Azelastine HydrochlorideSolution / drops.5 mg/mLIntraocularApotex Corp.2009-12-01Not applicableUs
Azelastine HydrochlorideSpray, metered137 ug/1NasalWest Ward Pharmaceuticals Corp.2014-10-27Not applicableUs
Azelastine HydrochlorideSolution / drops.5 mg/mLIntraocularSun Pharma Global FZE2010-05-31Not applicableUs
Azelastine HydrochlorideSpray, metered137 ug/1NasalApotex Corp.2010-03-01Not applicableUs
Azelastine HydrochlorideSpray, metered205.5 ug/1NasalApotex Corp.2014-07-07Not applicableUs
Azelastine HydrochlorideSpray, metered137 ug/.137mLNasalBreckenridge Pharmaceutical, Inc.2015-07-29Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
DymistaMeda Pharmaceuticals Inc.
TicalastShoreline Pharmaceuticals, Inc.
Salts
Name/CASStructureProperties
Azelastine Hydrochloride
79307-93-0
Thumb
  • InChI Key: YEJAJYAHJQIWNU-UHFFFAOYNA-N
  • Monoisotopic Mass: 417.137467851
  • Average Mass: 418.359
DBSALT000013
Categories
UNIIZQI909440X
CAS number58581-89-8
WeightAverage: 381.898
Monoisotopic: 381.160790112
Chemical FormulaC22H24ClN3O
InChI KeyMBUVEWMHONZEQD-UHFFFAOYSA-N
InChI
InChI=1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3
IUPAC Name
4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)-1,2-dihydrophthalazin-1-one
SMILES
CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O
Pharmacology
IndicationFor the symptomatic treatment of seasonal allergic rhinitis and non-allergic rhinitis, as well as symptomatic relief of ocular itching associated with allergic conjunctivitis.
Structured Indications
PharmacodynamicsAzelastine is a relatively selective histamine H1 antagonist, which inhibits the release of histamine and other mediators from cells (e.g. mast cells) involved in the allergic response. It has some affinity to H2 receptors. Based on in vitro studies using human cell lines, inhibition of other mediators involved in allergic reactions (e.g. leukotrienes and PAF) has been demonstrated with azelastine. Azelastine may also inhibit the accumulation and degranulation of eosinophils at the site of allergic inflammation.
Mechanism of actionAzelastine competes with histamine for the H1-receptor sites on effector cells and acts as an antagonist by inhibiting the release of histamine and other mediators involved in the allergic response.
TargetKindPharmacological actionActionsOrganismUniProt ID
Histamine H1 receptorProteinyes
antagonist
HumanP35367 details
Related Articles
AbsorptionAbsorption of azelastine following ocular administration was relatively low. Systemic bioavailability is approximately 40% after nasal administration.
Volume of distribution
  • 14.5 L/kg
Protein bindingIn-vitro studies in human plasma indicate that the plasma protein binding of azelastine and N-desmethylazelastine are approximately 88% and 97%, respectively.
Metabolism

Azelastine hydrochloride is oxidatively metabolized to the principal metabolite, N-desmethylazelastine, by the cytochrome P450 enzyme system, however the exact cytochrome P450 isoenzyme involved has not been determined. The major metabolite, desmethylazelastine, also has H1-receptor antagonist activity.

SubstrateEnzymesProduct
Azelastine
DesmethylazelastineDetails
Route of eliminationApproximately 75% of an oral dose of radiolabeled azelastine hydrochloride was excreted in the feces with less than 10% as unchanged azelastine. Azelastine hydrochloride is oxidatively metabolized to the principal metabolite, N-desmethylazelastine, by the cytochrome P450 enzyme system.
Half lifeElimination half-life (based on intravenous and oral administration) is 22 hours. Elimination half-life of the active metabolite, desmethylazelastine, is 54 hours (after oral administration of azelastine).
Clearance
  • 0.5 L/h/kg [symptomatic patients]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 Tetrafluoroethane1,1,1,2 Tetrafluoroethane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Azelastine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Azelastine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Azelastine is combined with 19-norandrostenedione.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Azelastine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Azelastine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Azelastine.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Azelastine is combined with 4-Androstenedione.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Azelastine.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Azelastine is combined with 5-androstenedione.Experimental, Illicit
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Azelastine.Experimental
AbciximabAzelastine may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Azelastine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Azelastine.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Azelastine is combined with Aceclofenac.Approved
AcenocoumarolAzelastine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Azelastine.Approved, Vet Approved
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Azelastine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Azelastine.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinAzelastine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Azelastine.Approved
adipiplonadipiplon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Azelastine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Azelastine.Approved
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Azelastine.Approved, Investigational
AlclometasoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Alclometasone.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Azelastine.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Alendronic acid.Approved
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Azelastine.Vet Approved
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Azelastine.Approved, Illicit
AliskirenAzelastine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Azelastine.Approved, Investigational
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Azelastine.Experimental, Illicit
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Investigational
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Azelastine.Approved, Illicit, Investigational
AlprenololAzelastine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Azelastine.Approved, Investigational
AlteplaseAzelastine may increase the anticoagulant activities of Alteplase.Approved
ALX-0081Azelastine may increase the anticoagulant activities of ALX-0081.Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Azelastine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Azelastine is combined with Amcinonide.Approved
AmikacinAzelastine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideAzelastine may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Azelastine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Azelastine.Approved, Investigational
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Azelastine.Approved
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Azelastine.Approved, Illicit
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Azelastine.Approved
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Azelastine.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Azelastine.Approved, Illicit
AmrubicinAzelastine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideAzelastine may increase the anticoagulant activities of Anagrelide.Approved
AncrodAzelastine may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Azelastine is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Azelastine is combined with Anisodamine.Investigational
AnistreplaseAzelastine may increase the anticoagulant activities of Anistreplase.Approved
annamycinAzelastine may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Azelastine is combined with Antipyrine.Approved
Antithrombin III humanAzelastine may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Azelastine may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanThe risk or severity of adverse effects can be increased when Azelastine is combined with Apixaban.Approved
ApramycinAzelastine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Azelastine is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Azelastine can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinAzelastine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinAzelastine may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanAzelastine may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Azelastine.Approved, Investigational
ArmodafinilThe metabolism of Azelastine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololAzelastine may decrease the antihypertensive activities of Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Azelastine.Approved, Investigational
ArtemetherThe metabolism of Azelastine can be decreased when combined with Artemether.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Azelastine resulting in a loss in efficacy.Approved
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Azelastine.Approved
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Azelastine.Approved
AstaxanthinAzelastine may increase the anticoagulant activities of Astaxanthin.Investigational
AtazanavirThe metabolism of Azelastine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Azelastine.Approved
AtomoxetineThe metabolism of Azelastine can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Azelastine.Approved, Investigational
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Azelastine.Vet Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Azapropazone.Withdrawn
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Azelastine.Approved
AzithromycinThe metabolism of Azelastine can be decreased when combined with Azithromycin.Approved
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Azelastine.Approved
BalsalazideAzelastine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Illicit
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Azelastine.Illicit
BatroxobinAzelastine may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminAzelastine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Azelastine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololAzelastine may decrease the antihypertensive activities of Befunolol.Experimental
BemiparinAzelastine may increase the anticoagulant activities of Bemiparin.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Azelastine.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Azelastine.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Benoxaprofen.Withdrawn
BenperidolBenperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
BenperidolThe risk or severity of adverse effects can be increased when Azelastine is combined with Benperidol.Investigational
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Azelastine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Azelastine.Approved, Illicit
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Azelastine.Approved
Benzylpenicilloyl PolylysineAzelastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Azelastine.Investigational
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Azelastine.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Azelastine.Approved, Vet Approved
BetaxololThe metabolism of Azelastine can be decreased when combined with Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Betulinic Acid.Investigational
BevantololAzelastine may decrease the antihypertensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Azelastine can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Azelastine.Approved, Investigational
BisoprololAzelastine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinAzelastine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Azelastine can be decreased when combined with Boceprevir.Approved
BopindololAzelastine may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Azelastine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Azelastine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Azelastine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Azelastine.Approved
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Azelastine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Azelastine.Approved
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Azelastine.Approved, Illicit
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Azelastine.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Azelastine.Approved, Investigational
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Azelastine.Approved
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Withdrawn
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Azelastine.Approved, Withdrawn
BucillamineThe risk or severity of adverse effects can be increased when Azelastine is combined with Bucillamine.Investigational
BucindololAzelastine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Azelastine is combined with Budesonide.Approved
BufuralolAzelastine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideAzelastine may decrease the diuretic activities of Bumetanide.Approved
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Azelastine.Approved, Investigational
BupranololAzelastine may decrease the antihypertensive activities of Bupranolol.Approved
BuprenorphineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Azelastine can be decreased when combined with Bupropion.Approved
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Azelastine.Approved, Investigational
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Azelastine.Approved, Illicit
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Azelastine.Vet Approved
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Azelastine.Approved, Illicit
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Azelastine.Approved
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Azelastine.Approved, Illicit
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Azelastine.Approved, Illicit, Vet Approved
ButylphthalideAzelastine may increase the antiplatelet activities of Butylphthalide.Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Azelastine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Azelastine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Azelastine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Azelastine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Azelastine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Azelastine.Experimental
CangrelorAzelastine may increase the anticoagulant activities of Cangrelor.Approved
CapecitabineThe metabolism of Azelastine can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Azelastine.Approved
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
CarbamazepineThe metabolism of Azelastine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Azelastine.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Azelastine.Approved
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Azelastine.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Azelastine.Approved
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Azelastine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Azelastine.Approved, Vet Approved, Withdrawn
CarteololAzelastine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolAzelastine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Azelastine is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Azelastine is combined with Celecoxib.Approved, Investigational
CeliprololAzelastine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Azelastine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Azelastine.Withdrawn
CertoparinAzelastine may increase the anticoagulant activities of Certoparin.Approved
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Azelastine.Approved
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Vet Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Azelastine.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Azelastine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Azelastine.Approved, Illicit
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Withdrawn
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Azelastine.Approved, Withdrawn
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Azelastine.Approved
ChloroquineThe metabolism of Azelastine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azelastine.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Azelastine is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Azelastine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Azelastine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Withdrawn
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Azelastine.Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Azelastine.Approved
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Azelastine.Approved
CholecalciferolThe metabolism of Azelastine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Azelastine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Azelastine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Azelastine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Azelastine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Azelastine.Approved
CinacalcetThe metabolism of Azelastine can be decreased when combined with Cinacalcet.Approved
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Azelastine.Approved, Vet Approved
CinoxacinAzelastine may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinAzelastine may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Azelastine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Azelastine.Approved
Citric AcidAzelastine may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Azelastine can be decreased when combined with Clarithromycin.Approved
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ClemastineThe metabolism of Azelastine can be decreased when combined with Clemastine.Approved
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Azelastine.Approved
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Azelastine.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Azelastine is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Azelastine is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Clodronate.Approved, Investigational, Vet Approved
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Azelastine.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Azelastine.Approved, Investigational
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
ClomipramineThe metabolism of Azelastine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
ClonazepamThe risk or severity of adverse effects can be increased when Azelastine is combined with Clonazepam.Approved, Illicit
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Azelastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Azelastine is combined with Clonixin.Approved
ClopidogrelThe metabolism of Azelastine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Azelastine.Vet Approved
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Azelastine.Approved, Illicit
ClotrimazoleThe metabolism of Azelastine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Azelastine.Approved
CobicistatThe serum concentration of Azelastine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Azelastine.Approved
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
CocaineThe metabolism of Azelastine can be decreased when combined with Cocaine.Approved, Illicit
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Azelastine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Azelastine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Azelastine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Azelastine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CollagenaseThe risk or severity of adverse effects can be increased when Azelastine is combined with Collagenase.Approved
ConivaptanThe serum concentration of Azelastine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Azelastine.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Azelastine is combined with Cortisone acetate.Approved
CrizotinibThe metabolism of Azelastine can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Azelastine is combined with Curcumin.Investigational
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Azelastine.Approved
CyclosporineAzelastine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Azelastine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Azelastine.Approved
Cyproterone acetateThe serum concentration of Azelastine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when Azelastine is combined with D-Limonene.Investigational
Dabigatran etexilateAzelastine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Azelastine can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Azelastine.Approved
DalteparinAzelastine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidAzelastine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Azelastine is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Azelastine.Approved
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Azelastine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Azelastine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Azelastine can be increased when it is combined with Darunavir.Approved
DasatinibDasatinib may increase the anticoagulant activities of Azelastine.Approved, Investigational
DaunorubicinAzelastine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Azelastine.Approved
DeferasiroxThe serum concentration of Azelastine can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideAzelastine may increase the anticoagulant activities of Defibrotide.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Azelastine is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Azelastine can be decreased when combined with Delavirdine.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Deoxycholic Acid.Approved
deramciclanederamciclane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Azelastine.Investigational
dersalazineThe risk or severity of adverse effects can be increased when Azelastine is combined with dersalazine.Investigational
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Azelastine.Approved
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DesipramineThe metabolism of Azelastine can be decreased when combined with Desipramine.Approved
DesirudinAzelastine may increase the anticoagulant activities of Desirudin.Approved
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Azelastine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Azelastine is combined with Desmopressin.Approved
DesmoteplaseAzelastine may increase the anticoagulant activities of Desmoteplase.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Azelastine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Azelastine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Azelastine is combined with Desvenlafaxine.Approved
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Azelastine.Vet Approved
DexamethasoneThe serum concentration of Azelastine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Azelastine is combined with Dexamethasone isonicotinate.Vet Approved
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Azelastine.Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Azelastine.Approved
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Azelastine.Approved, Vet Approved
DextranAzelastine may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Azelastine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Azelastine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Azelastine may increase the anticoagulant activities of Dextran 75.Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Azelastine.Approved, Illicit
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Azelastine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Withdrawn
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Azelastine.Approved, Illicit, Withdrawn
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Azelastine.Approved
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Azelastine.Approved, Illicit, Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Azelastine.Approved, Vet Approved
DicoumarolAzelastine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Azelastine.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Azelastine.Approved
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Azelastine is combined with Difenoxin.Approved, Illicit
DiflorasoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Azelastine is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Azelastine is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Azelastine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Azelastine.Approved
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Azelastine.Approved, Illicit
DihydroergotamineThe metabolism of Azelastine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Azelastine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Azelastine.Experimental, Illicit
DihydrostreptomycinAzelastine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Azelastine.Illicit
DiltiazemThe metabolism of Azelastine can be decreased when combined with Diltiazem.Approved
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Azelastine is combined with Dimenhydrinate.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Azelastine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Azelastine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Azelastine.Approved
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DiphenhydramineThe metabolism of Azelastine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Azelastine.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Azelastine.Approved
DitazoleAzelastine may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Azelastine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Azelastine.Approved, Investigational, Vet Approved
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Azelastine.Vet Approved
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Azelastine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Azelastine.Approved, Investigational
DoxorubicinAzelastine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Azelastine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Azelastine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
DronedaroneThe metabolism of Azelastine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
DrospirenoneAzelastine may increase the hyperkalemic activities of Drospirenone.Approved
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental, Illicit
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Azelastine.Experimental, Illicit
Drotrecogin alfaAzelastine may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Azelastine is combined with Droxicam.Approved
DuloxetineThe metabolism of Azelastine can be decreased when combined with Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Azelastine is combined with Duvelisib.Investigational
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Azelastine.Approved
E6201The risk or severity of adverse effects can be increased when Azelastine is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Azelastine is combined with Ebselen.Investigational
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental, Illicit
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Azelastine.Experimental, Illicit
ECGONINE METHYL ESTERECGONINE METHYL ESTER may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Azelastine.Experimental
EcopipamEcopipam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
EcopipamThe risk or severity of adverse effects can be increased when Azelastine is combined with Ecopipam.Investigational
Edetic AcidAzelastine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Azelastine.Approved
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
EfavirenzThe serum concentration of Azelastine can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Azelastine.Approved, Investigational
EliglustatThe metabolism of Azelastine can be decreased when combined with Eliglustat.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Azelastine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Azelastine.Approved
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Azelastine.Approved, Vet Approved
EnoxacinAzelastine may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinAzelastine may increase the anticoagulant activities of Enoxaparin.Approved
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Azelastine.Approved, Investigational
EnzalutamideThe serum concentration of Azelastine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Azelastine.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Azelastine is combined with Epirizole.Approved
EpirubicinAzelastine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneAzelastine may decrease the antihypertensive activities of Eplerenone.Approved
eplivanserineAzelastine may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolEpoprostenol may increase the antiplatelet activities of Azelastine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azelastine.Approved
EptifibatideAzelastine may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Azelastine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Azelastine is combined with Equilin.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Azelastine.Approved, Investigational
ErythromycinThe metabolism of Azelastine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Azelastine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Azelastine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololAzelastine may decrease the antihypertensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Azelastine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Azelastine.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Azelastine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Azelastine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Azelastine.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Azelastine is combined with Estrone sulfate.Approved
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Azelastine.Approved
Etacrynic acidAzelastine may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Azelastine.Approved, Investigational
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Withdrawn
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Azelastine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Azelastine.Approved
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Azelastine.Approved
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Azelastine.Approved
Ethyl biscoumacetateAzelastine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Azelastine.Withdrawn
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Azelastine.Approved, Illicit
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Azelastine.Approved, Illicit
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Azelastine.Approved
Etidronic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Etidronic acid.Approved
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Withdrawn
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Azelastine.Withdrawn
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Azelastine.Approved
EtodolacThe risk or severity of adverse effects can be increased when Azelastine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Azelastine is combined with Etofenamate.Approved
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Azelastine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Azelastine.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Azelastine is combined with Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Illicit, Vet Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Azelastine.Illicit, Vet Approved
EtravirineThe serum concentration of Azelastine can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Azelastine is combined with Evening primrose oil.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Azelastine.Approved
exisulindThe risk or severity of adverse effects can be increased when Azelastine is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Azelastine.Approved
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ezogabine.Approved
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Azelastine.Approved
FelodipineThe metabolism of Azelastine can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Azelastine is combined with Fenbufen.Approved
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Withdrawn
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Azelastine.Approved, Illicit, Withdrawn
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Azelastine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Azelastine.Vet Approved
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Investigational, Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Azelastine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Azelastine.Approved
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Azelastine.Approved
FibrinolysinAzelastine may increase the anticoagulant activities of Fibrinolysin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Azelastine.Approved
FleroxacinAzelastine may increase the neuroexcitatory activities of Fleroxacin.Approved
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Azelastine is combined with Flibanserin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Azelastine.Approved, Withdrawn
FloxuridineThe metabolism of Azelastine can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Azelastine is combined with fluasterone.Investigational
FluconazoleThe metabolism of Azelastine can be decreased when combined with Fluconazole.Approved
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Azelastine.Approved, Illicit
FludrocortisoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Fludrocortisone.Approved
FluindioneAzelastine may increase the anticoagulant activities of Fluindione.Investigational
FlumequineAzelastine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Flumethasone.Approved, Vet Approved
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Azelastine is combined with Flunarizine.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Azelastine is combined with Flunisolide.Approved, Investigational
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Azelastine.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Azelastine is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Azelastine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Azelastine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Withdrawn
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Azelastine.Approved, Withdrawn
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Azelastine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Azelastine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Azelastine is combined with Flurandrenolide.Approved
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Azelastine.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Azelastine.Approved, Investigational
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Azelastine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Azelastine.Approved
Fluticasone PropionateFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Azelastine.Approved
FluvastatinThe metabolism of Azelastine can be decreased when combined with Fluvastatin.Approved
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
FluvoxamineThe metabolism of Azelastine can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Azelastine.Approved, Nutraceutical, Vet Approved
FondaparinuxAzelastine may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumAzelastine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Azelastine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Azelastine is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Azelastine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Azelastine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Azelastine.Approved
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
FosphenytoinThe metabolism of Azelastine can be increased when combined with Fosphenytoin.Approved
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Azelastine.Approved, Illicit
FramycetinAzelastine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideAzelastine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Azelastine can be increased when it is combined with Fusidic Acid.Approved
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Azelastine.Approved, Investigational
gabapentin enacarbilgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Azelastine is combined with gabapentin enacarbil.Approved
GabexateAzelastine may increase the anticoagulant activities of Gabexate.Investigational
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Azelastine.Approved, Illicit
GarenoxacinAzelastine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinAzelastine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Azelastine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Azelastine.Approved
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Azelastine.Approved, Withdrawn
GemfibrozilThe metabolism of Azelastine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinAzelastine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinAzelastine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinAzelastine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AAzelastine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GepironeGepirone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
GepironeThe risk or severity of adverse effects can be increased when Azelastine is combined with Gepirone.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Azelastine.Approved
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Azelastine.Approved, Illicit
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Azelastine.Approved
GrepafloxacinAzelastine may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Azelastine is combined with Guanfacine.Approved, Investigational
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Withdrawn
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Azelastine.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Azelastine is combined with Haloperidol.Approved
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Azelastine.Approved, Vet Approved
HE3286The risk or severity of adverse effects can be increased when Azelastine is combined with HE3286.Investigational
HeparinAzelastine may increase the anticoagulant activities of Heparin.Approved, Investigational
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Azelastine.Approved, Illicit
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Azelastine.Approved
HigenamineAzelastine may increase the anticoagulant activities of Higenamine.Investigational
HirulogAzelastine may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Azelastine is combined with HMPL-004.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Azelastine.Approved, Investigational
HydralazineAzelastine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Azelastine.Approved, Vet Approved
HydrocodoneHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Azelastine.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Azelastine.Approved
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Azelastine.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Azelastine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Hygromycin BAzelastine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Azelastine is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Azelastine.Approved
IbudilastAzelastine may increase the antiplatelet activities of Ibudilast.Approved, Investigational
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Azelastine.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Azelastine is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Azelastine is combined with Icatibant.Approved
Icosapent ethylAzelastine may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
IdarubicinAzelastine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Azelastine can be increased when it is combined with Idelalisib.Approved
idraparinuxAzelastine may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilAzelastine may increase the antiplatelet activities of Ifenprodil.Approved, Withdrawn
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Iloperidone.Approved
IloprostIloprost may increase the antiplatelet activities of Azelastine.Approved, Investigational
ImatinibThe metabolism of Azelastine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Azelastine.Investigational
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Azelastine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Azelastine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Azelastine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Azelastine.Approved
IndenololAzelastine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Azelastine can be decreased when combined with Indinavir.Approved
IndobufenAzelastine may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Azelastine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Indoprofen.Withdrawn
INNO-206Azelastine may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Azelastine can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Azelastine.Approved, Investigational
IsavuconazoniumThe metabolism of Azelastine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Azelastine.Approved, Vet Approved
IsoniazidThe metabolism of Azelastine can be decreased when combined with Isoniazid.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Azelastine is combined with Isoxicam.Withdrawn
IsradipineThe metabolism of Azelastine can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Azelastine is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Azelastine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Azelastine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Azelastine.Approved, Vet Approved
KanamycinAzelastine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
Kct 0809Azelastine may increase the anticoagulant activities of Kct 0809.Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Kebuzone.Experimental
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Azelastine.Approved, Vet Approved
KetanserinAzelastine may increase the antiplatelet activities of Ketanserin.Investigational
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Azelastine.Approved
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Azelastine.Approved
KetoconazoleThe metabolism of Azelastine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Azelastine.Approved
LabetalolAzelastine may decrease the antihypertensive activities of Labetalol.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Azelastine.Approved, Investigational
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Azelastine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Azelastine.Approved, Investigational
LapatinibThe metabolism of Azelastine can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Azelastine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Azelastine.Approved
LeflunomideThe metabolism of Azelastine can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Azelastine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Azelastine.Approved
LepirudinAzelastine may increase the anticoagulant activities of Lepirudin.Approved
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Azelastine.Approved, Investigational
LevobunololAzelastine may decrease the antihypertensive activities of Levobunolol.Approved
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Azelastine.Approved
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Levocabastine.Approved
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Azelastine is combined with Levocetirizine.Approved
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Azelastine is combined with Levodopa.Approved
LevofloxacinAzelastine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Azelastine.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Azelastine.Approved
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Azelastine.Approved
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
LidocaineThe metabolism of Azelastine can be decreased when combined with Lidocaine.Approved, Vet Approved
LimaprostLimaprost may increase the antiplatelet activities of Azelastine.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Azelastine.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Azelastine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Azelastine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Azelastine is combined with Lisofylline.Investigational
LithiumLithium may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LithiumThe serum concentration of Lithium can be increased when it is combined with Azelastine.Approved
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Illicit
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Azelastine.Illicit
LomefloxacinAzelastine may increase the neuroexcitatory activities of Lomefloxacin.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Azelastine.Approved
LopinavirThe metabolism of Azelastine can be decreased when combined with Lopinavir.Approved
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Azelastine.Approved
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Azelastine.Approved
LorcaserinThe metabolism of Azelastine can be decreased when combined with Lorcaserin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Azelastine is combined with Lornoxicam.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Azelastine.Approved
LovastatinThe metabolism of Azelastine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Azelastine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Loxoprofen.Approved
Lu AA21004Lu AA21004 may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Azelastine.Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Azelastine.Approved, Investigational
LuliconazoleThe serum concentration of Azelastine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Azelastine can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Azelastine can be decreased when combined with Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Azelastine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Azelastine.Vet Approved
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Azelastine.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Azelastine is combined with Magnesium salicylate.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Azelastine.Approved, Investigational
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Azelastine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Azelastine.Approved
ME-609The risk or severity of adverse effects can be increased when Azelastine is combined with ME-609.Investigational
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Azelastine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azelastine.Approved, Vet Approved
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Azelastine.Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Azelastine.Approved
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Nutraceutical, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Azelastine.Approved, Nutraceutical, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Azelastine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Azelastine.Approved, Vet Approved
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Azelastine.Approved
MephedroneMephedrone may decrease the sedative activities of Azelastine.Investigational
MephentermineMephentermine may decrease the sedative activities of Azelastine.Approved
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Azelastine.Approved, Vet Approved
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Azelastine.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mesalazine.Approved
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Azelastine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Azelastine is combined with Metamizole.Withdrawn
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Azelastine.Approved
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MethadoneThe metabolism of Azelastine can be decreased when combined with Methadone.Approved
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Azelastine.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Azelastine.Approved, Illicit
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Withdrawn
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Azelastine.Withdrawn
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Illicit, Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Azelastine.Illicit, Withdrawn
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Azelastine.Approved, Vet Approved
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Azelastine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Azelastine.Approved
MethotrimeprazineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Azelastine.Approved, Vet Approved
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Azelastine is combined with Methsuximide.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azelastine.Approved
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Azelastine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Azelastine.Approved, Vet Approved
MetipranololAzelastine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Azelastine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Azelastine.Approved, Investigational
MetrizamideAzelastine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MetyrosineAzelastine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Azelastine can be decreased when combined with Mexiletine.Approved
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Azelastine.Approved, Illicit
MifepristoneThe serum concentration of Azelastine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Azelastine is combined with Milnacipran.Approved
MilrinoneMilrinone may increase the antiplatelet activities of Azelastine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Azelastine.Approved
MirtazapineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Azelastine.Approved
MitotaneThe serum concentration of Azelastine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Azelastine.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mizoribine.Investigational
MMDAMMDA may decrease the sedative activities of Azelastine.Experimental, Illicit
MoclobemideThe metabolism of Azelastine can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Azelastine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Azelastine.Approved
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Azelastine.Approved
MometasoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Azelastine.Approved
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Azelastine.Approved, Investigational
MoxifloxacinAzelastine may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Azelastine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Mycophenolic acid.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Azelastine.Approved
NadroparinAzelastine may increase the anticoagulant activities of Nadroparin.Approved
NafamostatAzelastine may increase the anticoagulant activities of Nafamostat.Investigational
NafcillinThe serum concentration of Azelastine can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Azelastine.Approved
NaftopidilAzelastine may increase the antiplatelet activities of Naftopidil.Investigational
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Azelastine.Approved
Nalidixic AcidAzelastine may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Azelastine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Azelastine.Approved, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Azelastine.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Azelastine is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Azelastine is combined with NCX 4016.Investigational
NeamineAzelastine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneThe metabolism of Azelastine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Azelastine can be decreased when combined with Nelfinavir.Approved
NemonoxacinAzelastine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinAzelastine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Azelastine is combined with Nepafenac.Approved
NetilmicinAzelastine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NetupitantThe serum concentration of Azelastine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Azelastine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Azelastine can be decreased when combined with Nicardipine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Azelastine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Azelastine can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Azelastine is combined with Nimesulide.Approved, Withdrawn
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Azelastine.Approved
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Azelastine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Azelastine is combined with Nitroaspirin.Investigational
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Azelastine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Azelastine.Approved
NorfloxacinAzelastine may increase the neuroexcitatory activities of Norfloxacin.Approved
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Azelastine.Approved, Illicit
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Azelastine.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Azelastine is combined with Obinutuzumab.Approved
OfloxacinAzelastine may increase the neuroexcitatory activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Azelastine.Approved, Investigational
OlaparibThe metabolism of Azelastine can be decreased when combined with Olaparib.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Azelastine is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Azelastine.Approved, Investigational
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Azelastine.Approved
OlsalazineAzelastine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Azelastine is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Azelastine.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Azelastine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Azelastine.Approved
OmeprazoleThe metabolism of Azelastine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Azelastine.Approved
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Azelastine.Approved, Illicit
OrgoteinThe risk or severity of adverse effects can be increased when Azelastine is combined with Orgotein.Vet Approved
OrphenadrineAzelastine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Azelastine.Investigational
OsimertinibThe serum concentration of Azelastine can be increased when it is combined with Osimertinib.Approved
OtamixabanAzelastine may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxaprozin.Approved
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Azelastine.Approved
OxetacaineOxetacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
OxetacaineThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxetacaine.Investigational
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Azelastine.Approved
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Azelastine.Approved
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Azelastine.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational, Vet Approved
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Azelastine.Approved, Investigational, Vet Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Azelastine.Approved, Vet Approved
PalbociclibThe serum concentration of Azelastine can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Azelastine.Approved
PamidronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Pamidronate.Approved
PanobinostatThe serum concentration of Azelastine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Azelastine can be decreased when combined with Pantoprazole.Approved
ParaldehydeAzelastine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Azelastine is combined with Parecoxib.Approved
ParnaparinAzelastine may increase the anticoagulant activities of Parnaparin.Approved
ParomomycinAzelastine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineThe metabolism of Azelastine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Azelastine.Approved
PazufloxacinAzelastine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinAzelastine may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Azelastine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololAzelastine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Azelastine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
PentobarbitalThe metabolism of Azelastine can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Azelastine.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Azelastine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PerazinePerazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
PerazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Azelastine.Approved
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Azelastine.Approved
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Azelastine.Approved
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Azelastine.Approved
PhenindioneAzelastine may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PhenobarbitalThe metabolism of Azelastine can be increased when combined with Phenobarbital.Approved
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Azelastine.Approved
PhenprocoumonAzelastine may increase the anticoagulant activities of Phenprocoumon.Approved
PhenterminePhentermine may decrease the sedative activities of Azelastine.Approved, Illicit
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Azelastine.Approved, Vet Approved
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
PhenytoinThe metabolism of Azelastine can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azelastine.Approved, Investigational
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Azelastine.Approved
PindololAzelastine may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Azelastine can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Azelastine.Approved
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pipotiazine.Approved
PirarubicinAzelastine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideAzelastine may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Azelastine is combined with Pirfenidone.Investigational
PiritramidePiritramide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Azelastine is combined with Piritramide.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Azelastine.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Azelastine.Approved
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PizotifenThe risk or severity of adverse effects can be increased when Azelastine is combined with Pizotifen.Approved
PlasminAzelastine may increase the anticoagulant activities of Plasmin.Investigational
PlicamycinAzelastine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Azelastine.Approved
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Azelastine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Azelastine.Approved
PosaconazoleThe metabolism of Azelastine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololAzelastine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Azelastine.Approved
PramipexoleAzelastine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Azelastine.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Azelastine is combined with Prasterone.Approved, Nutraceutical
PrasugrelAzelastine may increase the anticoagulant activities of Prasugrel.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Azelastine.Approved
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Azelastine.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Azelastine.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Azelastine is combined with Prednicarbate.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Azelastine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Azelastine.Approved, Vet Approved
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Investigational
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Azelastine.Approved, Illicit, Investigational
PregnanolonePregnanolone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Pregnanolone.Investigational
PregnenoloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Pregnenolone.Experimental
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Azelastine.Approved
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
PrimidoneThe metabolism of Azelastine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Azelastine can be increased when it is combined with Probenecid.Approved
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Azelastine.Approved, Investigational, Vet Approved
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Azelastine.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Azelastine.Approved, Vet Approved
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
PromazineThe metabolism of Azelastine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PromethazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Azelastine is combined with Propacetamol.Approved
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Azelastine.Approved, Vet Approved
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Azelastine.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Azelastine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Azelastine.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Azelastine.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Azelastine.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Azelastine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Azelastine.Vet Approved
Protein CAzelastine may increase the anticoagulant activities of Protein C.Approved
Protein S humanAzelastine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeAzelastine may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Azelastine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Azelastine.Approved
PrulifloxacinAzelastine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Azelastine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Azelastine.Approved
PTC299The risk or severity of adverse effects can be increased when Azelastine is combined with PTC299.Investigational
PuromycinAzelastine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Azelastine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Azelastine.Approved, Illicit
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Azelastine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Azelastine.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Azelastine.Approved
QuinidineThe metabolism of Azelastine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Azelastine.Approved
RabeprazoleThe metabolism of Azelastine can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideRaclopride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Azelastine is combined with Raclopride.Investigational
RamatrobanAzelastine may increase the antiplatelet activities of Ramatroban.Investigational
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
RamelteonThe risk or severity of adverse effects can be increased when Azelastine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Azelastine.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Azelastine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Azelastine.Approved, Investigational
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Azelastine.Approved
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Withdrawn
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Azelastine.Approved, Withdrawn
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Azelastine.Approved
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Azelastine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Azelastine is combined with Resveratrol.Experimental, Investigational
ReteplaseAzelastine may increase the anticoagulant activities of Reteplase.Approved
ReviparinAzelastine may increase the anticoagulant activities of Reviparin.Approved
RibostamycinAzelastine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RidogrelAzelastine may increase the antiplatelet activities of Ridogrel.Approved
RifabutinThe metabolism of Azelastine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Azelastine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Azelastine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Azelastine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Risedronate.Approved, Investigational
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Azelastine.Approved, Investigational
RitanserinRitanserin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
RitanserinThe risk or severity of adverse effects can be increased when Azelastine is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative activities of Azelastine.Investigational
RitonavirThe metabolism of Azelastine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanAzelastine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Azelastine is combined with Rofecoxib.Investigational, Withdrawn
RolapitantThe metabolism of Azelastine can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Azelastine.Approved, Investigational
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Azelastine.Vet Approved
RopiniroleAzelastine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Azelastine.Approved
RosiglitazoneThe metabolism of Azelastine can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinAzelastine may increase the neuroexcitatory activities of Rosoxacin.Approved
RotigotineAzelastine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Azelastine.Approved
S-EthylisothioureaS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Azelastine.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Azelastine.Approved
Sage 547Sage 547 may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
Sage 547The risk or severity of adverse effects can be increased when Azelastine is combined with Sage 547.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Azelastine is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Azelastine is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Azelastine.Experimental
SaquinavirThe metabolism of Azelastine can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Azelastine.Investigational
SCH-530348Azelastine may increase the antiplatelet activities of SCH-530348.Investigational
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Azelastine.Approved
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
SecobarbitalThe metabolism of Azelastine can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Azelastine.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Azelastine is combined with Seratrodast.Approved, Investigational
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Withdrawn
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Azelastine.Approved, Withdrawn
SertralineThe metabolism of Azelastine can be decreased when combined with Sertraline.Approved
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Azelastine.Approved, Vet Approved
SildenafilThe metabolism of Azelastine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Azelastine.Approved
SiltuximabThe serum concentration of Azelastine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Azelastine can be increased when it is combined with Simeprevir.Approved
SisomicinAzelastine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Azelastine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Azelastine.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Azelastine.Approved, Investigational
SotalolAzelastine may decrease the antihypertensive activities of Sotalol.Approved
SP1049CAzelastine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinAzelastine may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinAzelastine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Azelastine.Experimental
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Azelastine.Approved
SpironolactoneAzelastine may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Azelastine is combined with SRT501.Investigational
St. John's WortThe serum concentration of Azelastine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolStiripentol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
StiripentolThe serum concentration of Azelastine can be increased when it is combined with Stiripentol.Approved
StreptokinaseAzelastine may increase the anticoagulant activities of Streptokinase.Approved
StreptomycinAzelastine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinAzelastine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Azelastine.Approved, Investigational
SulfadiazineThe metabolism of Azelastine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Azelastine can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineAzelastine may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Azelastine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Azelastine.Approved
SulodexideAzelastine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Azelastine.Approved
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Azelastine.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Azelastine.Approved, Withdrawn
SuvorexantSuvorexant may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Azelastine.Approved, Investigational
TacrolimusAzelastine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Azelastine.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Azelastine.Approved
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Azelastine.Approved
TandospironeTandospirone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Azelastine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Azelastine is combined with Tasimelteon.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Azelastine.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Azelastine.Experimental
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Technetium Tc-99m Medronate.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Azelastine.Approved
TelaprevirThe metabolism of Azelastine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Azelastine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azelastine.Approved, Investigational
TemafloxacinAzelastine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Azelastine.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Azelastine.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Azelastine.Approved
TenecteplaseAzelastine may increase the anticoagulant activities of Tenecteplase.Approved
TenofovirThe risk or severity of adverse effects can be increased when Azelastine is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Azelastine.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Azelastine is combined with Tepoxalin.Vet Approved
TerbinafineThe metabolism of Azelastine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Azelastine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneAzelastine may increase the antiplatelet activities of Tesmilifene.Investigational
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tetrabenazine.Approved
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Azelastine.Approved, Vet Approved
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Azelastine.Investigational
ThalidomideAzelastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Azelastine can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Azelastine.Approved, Vet Approved
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Azelastine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Azelastine.Approved
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Azelastine.Approved
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Azelastine.Approved
TiaprideTiapride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
TiaprideThe risk or severity of adverse effects can be increased when Azelastine is combined with Tiapride.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Azelastine.Approved
TiclopidineThe metabolism of Azelastine can be decreased when combined with Ticlopidine.Approved
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Azelastine.Vet Approved
TiludronateThe risk or severity of adverse effects can be increased when Azelastine is combined with Tiludronate.Approved, Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Azelastine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tinoridine.Investigational
TinzaparinAzelastine may increase the anticoagulant activities of Tinzaparin.Approved
TipranavirTipranavir may increase the antiplatelet activities of Azelastine.Approved, Investigational
TirofibanAzelastine may increase the anticoagulant activities of Tirofiban.Approved
TixocortolThe risk or severity of adverse effects can be increased when Azelastine is combined with Tixocortol.Approved
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Azelastine.Approved
TobramycinAzelastine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Azelastine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Azelastine can be decreased when combined with Tolbutamide.Approved
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Withdrawn
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Azelastine.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Azelastine is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Azelastine.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Azelastine.Approved
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Azelastine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Azelastine.Approved, Investigational
TorasemideAzelastine may decrease the diuretic activities of Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Azelastine.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Azelastine is combined with Tositumomab.Approved
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Azelastine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Azelastine.Approved
TranilastThe risk or severity of adverse effects can be increased when Azelastine is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Experimental
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Azelastine.Experimental
TranylcypromineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TranylcypromineThe metabolism of Azelastine can be decreased when combined with Tranylcypromine.Approved
TrapidilAzelastine may increase the antiplatelet activities of Trapidil.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Azelastine.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Azelastine.Approved
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Azelastine.Approved, Investigational
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Azelastine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Azelastine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneAzelastine may decrease the antihypertensive activities of Triamterene.Approved
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Azelastine.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Azelastine.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Azelastine.Approved
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Vet Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Azelastine.Approved, Vet Approved
TriflusalAzelastine may increase the anticoagulant activities of Triflusal.Approved
TrimethoprimThe metabolism of Azelastine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Azelastine.Approved
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Azelastine.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Azelastine is combined with Trisalicylate-choline.Approved
TrovafloxacinAzelastine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
Uc1010Uc1010 may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Investigational
Uc1010The risk or severity of adverse effects can be increased when Azelastine is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Azelastine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Azelastine.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Azelastine.Approved
UrokinaseAzelastine may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Azelastine is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Azelastine.Approved, Investigational
ValrubicinAzelastine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Azelastine can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Azelastine.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Azelastine.Approved
VemurafenibThe serum concentration of Azelastine can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Azelastine.Approved
VenlafaxineThe metabolism of Azelastine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Azelastine can be decreased when combined with Verapamil.Approved
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Azelastine is combined with Vigabatrin.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Azelastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Azelastine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Azelastine.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Azelastine.Approved, Nutraceutical, Vet Approved
VorapaxarAzelastine may increase the anticoagulant activities of Vorapaxar.Approved
VoriconazoleThe metabolism of Azelastine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Azelastine.Approved
WarfarinAzelastine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranAzelastine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Azelastine.Vet Approved
Ym150Azelastine may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Azelastine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Illicit, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Azelastine.Approved, Illicit, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Azelastine is combined with Zaltoprofen.Approved
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Azelastine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Azelastine.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Azelastine.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Azelastine is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ZiprasidoneThe metabolism of Azelastine can be decreased when combined with Ziprasidone.Approved
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Vet Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Azelastine.Vet Approved
Zoledronic acidThe risk or severity of adverse effects can be increased when Azelastine is combined with Zoledronic acid.Approved
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Azelastine is combined with Zomepirac.Withdrawn
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Azelastine.Approved, Investigational
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Azelastine.Approved
ZorubicinAzelastine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Azelastine.Approved
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Azelastine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Yutaka Morita, Noritoshi Koyama, Shigemitsu Ohsawa, “Methods employing stable preparation containing azelastine hydrochloride.” U.S. Patent US6117864, issued December, 1990.

US6117864
General References
  1. Horak F: Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis. Ther Clin Risk Manag. 2008 Oct;4(5):1009-22. [PubMed:19209282 ]
  2. Bernstein JA: Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin. 2007 Oct;23(10):2441-52. [PubMed:17723160 ]
External Links
ATC CodesR01AC03S01GX07R06AX19
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (17.5 KB)
MSDSDownload (36.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.982
Caco-2 permeable-0.5102
P-glycoprotein substrateSubstrate0.7034
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.9563
Renal organic cation transporterInhibitor0.6812
CYP450 2C9 substrateNon-substrate0.7501
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.8204
CYP450 1A2 substrateInhibitor0.6371
CYP450 2C9 inhibitorNon-inhibitor0.8114
CYP450 2D6 inhibitorNon-inhibitor0.568
CYP450 2C19 inhibitorNon-inhibitor0.6934
CYP450 3A4 inhibitorNon-inhibitor0.5902
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7266
Ames testNon AMES toxic0.6567
CarcinogenicityNon-carcinogens0.878
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0597 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7885
hERG inhibition (predictor II)Inhibitor0.7391
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc richmond hill
  • Sun pharma global fze
  • Meda pharmaceuticals inc
  • Meda pharmaceuticals meda pharmaceuticals inc
  • Apotex inc
  • Meda pharmaceuticals
Packagers
Dosage forms
FormRouteStrength
Spray, meteredNasal137 ug/1
Spray, meteredNasal205.5 ug/1
SprayNasal205.5 ug/1
Solution / dropsOphthalmic.5 mg/mL
Spray, meteredNasal137 ug/.137mL
Spray, meteredNasal
Solution / dropsIntraocular.5 mg/mL
Kit
Prices
Unit descriptionCostUnit
Optivar 0.05% Solution 6ml Bottle120.26USD bottle
Astelin 137 mcg/spray Solution 30ml Bottle117.27USD bottle
Azelastine HCl 0.05% Solution 6ml Bottle108.23USD bottle
Optivar 0.05% drops19.27USD ml
Azelastine hcl 0.05% drops17.35USD ml
Astelin 137 mcg nasal spray3.71USD ml
Astepro 137 mcg nasal spray3.61USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5164194 No1994-05-012011-05-01Us
US8071073 No2008-06-042028-06-04Us
US8163723 No2003-08-292023-08-29Us
US8168620 No2006-02-242026-02-24Us
US8518919 No2005-11-222025-11-22Us
US9259428 No2003-06-132023-06-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point225 °C (hydrochloride salt)Not Available
water solubilitySparingly soluble (hydrochloride salt)Not Available
logP4.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0092 mg/mLALOGPS
logP3.81ALOGPS
logP4.04ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)8.88ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area35.91 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity110.52 m3·mol-1ChemAxon
Polarizability41.54 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phthalazinones. These are compounds containing a phthalazine bearing a ketone group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassPhthalazines
Direct ParentPhthalazinones
Alternative Parents
Substituents
  • Phthalazinone
  • Pyridazinone
  • Halobenzene
  • Chlorobenzene
  • Azepane
  • Benzenoid
  • Pyridazine
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Lactam
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Casale TB: The interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites. J Allergy Clin Immunol. 1989 Apr;83(4):771-6. [PubMed:2540229 ]
  2. Conde Hernandez DJ, Palma Aqilar JL, Delgado Romero J: Comparison of azelastine nasal spray and oral ebastine in treating seasonal allergic rhinitis. Curr Med Res Opin. 1995;13(6):299-304. [PubMed:8829888 ]
  3. Antepara I, Jauregui I, Basomba A, Cadahia A, Feo F, Garcia JJ, Gonzalo MA, Luna I, Rubio M, Vazquez M: [Investigation of the efficacy and tolerability of azelastine nasal spray versus ebastine tablets in patients with seasonal allergic rhinitis]. Allergol Immunopathol (Madr). 1998 Jan-Feb;26(1):9-16. [PubMed:9585822 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Horak F: Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis. Ther Clin Risk Manag. 2008 Oct;4(5):1009-22. [PubMed:19209282 ]
  6. Bernstein JA: Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin. 2007 Oct;23(10):2441-52. [PubMed:17723160 ]
  7. Golden SJ, Craig TJ: Efficacy and safety of azelastine nasal spray for the treatment of allergic rhinitis. J Am Osteopath Assoc. 1999 Jul;99(7 Suppl):S7-12. [PubMed:10478514 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13. [PubMed:11231118 ]
  2. Hu YP, Robert J: Azelastine and flezelastine as reversing agents of multidrug resistance: pharmacological and molecular studies. Biochem Pharmacol. 1995 Jul 17;50(2):169-75. [PubMed:7632160 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:48